Synchronous Ovarian and Cervical Malignancies: A Case Report of Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and Niraparib Maintenance Authors: Xinqi Lv, Lihua Tang, YinPing Ma, Li Zhou Published: 2026 ABSTRACT AbstractPurposeThe coexistence of ovarian carcinosarcoma, contralateral high-grade serous ovarian carcinoma, and synchronous cervical squamous cell carcinoma as multiple primary gynecologic malignancies is exceedingly rare. The tumor biology of such synchronous multiple primary malignancies (MPMNs), including pathogenesis, disease progression and prognostic impact, is not well established.Patients and MethodsHere we report the case of a 66-year-old woman diagnosed with distinct tumors: left ovarian carcinosarcoma, right ovarian high-grade serous carcinoma, and cervical squamous cell carcinoma, and review the literature on multiple primary malignancies (MPMNs).ResultsFollowing preoperative neoadjuvant chemotherapy with three cycles of paclitaxel plus carboplatin, the patient achieved a significant reduction in tumor volume and underwent interval cytoreductive surgery. After that, she received five cycles of adjuvant chemotherapy: two cycles of paclitaxel plus carboplatin (with bevacizumab added in the second cycle), followed by three cycles of paclitaxel plus cisplatin. Despite testing negative for HRD and BRCA mutations, she subsequently received maintenance therapy with niraparib. This treatment led to a progression-free survival of nearly one year. Although her ovarian cancer later recurred, her overall survival exceeded three years.ConclusionMultiple primary malignant neoplasms (MPMNs) are rare and there are no unified clinical guideline for this situation. This report is valuable for enhancing clinical recognition of this rare condition and contributes to optimizing and personalizing MPMNs care.Keywords: MPMNs, cervical cancer, ovarian high-grade serous carcinoma, ovarian carcinosarcoma, individual therapy Introduction Multiple primary malignant neoplasms (MPMNs) are defined as the occurrence of two or more histologically distinct primary malignancies arising in the same individual, either synchronously or metachronously.1 According to the temporal interval between tumor diagnoses, MPMNs are classified as synchronous when identified within 6 months and metachronous when diagnosed beyond this interval.1 Within gynecologic oncology, synchronous primary tumors are uncommon, with an estimated incidence of 1–2% among women with malignancies of the female reproductive tract.2 Notably, synchronous endometrial and ovarian carcinomas constitute the predominant subset, accounting for 50–70% of such cases. In contrast, the concurrence of primary cervical and ovarian malignancies is exceedingly rare.3,4 Here, we present the case of a 66-year-old woman diagnosed with synchronous primary cervical cancer and ovarian cancer. This report aims to enhance clinical recognition of this rare condition and to contribute to improved diagnostic accuracy and therapeutic decision-making. The molecular mechanisms among these tumor types need special attention. In the gene test of this case, the patient was found to have a positive TP53 mutation. TP53 is the most frequently mutated gene in human cancers, and its functional loss mutations play an important role in the development of high-grade serous carcinoma (HGSOC) and ovarian carcinosarcoma. In HGSOC, TP53 mutations are present in almost all cases (>96%),5 resulting in genomic instability, aggressive behavior, and treatment resistance.6 Ovarian carcinosarcoma also has a high frequency of TP53 mutations, followed by complex genomic rearrangement.7 In cervical cancer, TP53 mutations are not the main driver, but HPV cancer proteins (E6) can decrease the expression of p53 protein, functionally inactivating the p53 pathway and causing similar genomic integrity disruption.8 Therefore, among the three histological types involved in this case, p53 pathway disruption represents a convergent biological mechanism that may predispose to the occurrence of simultaneous aggressive malignant tumors. Ovarian carcinosarcoma (OCS), also known as malignant mixed müllerian tumor (MMMT), is a rare and highly aggressive subtype of ovarian carcinoma, accounting for approximately 1–4% of all ovarian cancers.9,10 The majority of patients present with advanced stage of disease at the time of diagnosis, resulting in poor prognosis and high risk of recurrence.11 Currently, no specific international guidelines have been established for the management of OCS. In clinical practice, treatment approaches are largely extrapolated from those for epithelial ovarian carcinoma (EOC), as recommended by the National Comprehensive Cancer Network (NCCN) guidelines. Cytoreductive surgery followed by chemotherapy remains the cornerstone of management. Among the various subtypes of ovarian cancer (OC), high-grade serous ovarian carcinoma (HGSOC) is the most common and by far the most lethal.12,13 Due to the lack of specific early warning signs and a nonspecific symptoms, patients with HGSOC are frequently diagnosed at an advanced stage. Moreover, although the initial response to first-line platinum-based chemotherapy is typically favorable, recurrence is almost inevitable, and the disease eventually develops resistance to treatment. This results in a 5-year survival rate of less than 30% for epithelial ovarian cancer in the United States.12,14 Recently, poly (ADP-ribose) polymerase (PARP) inhibitors and antiangiogenic agents have entered clinical practice after demonstrating efficacy in improving progression-free survival in recent clinical trials. Squamous cell carcinoma accounts for more than 75% of all cervical cancers and represents a major contributor to the overall disease burden.15,16 Persistent infection by high-risk human papillomavirus (HR-HPV) is the primary cause of cervical cancer. Patients with early-stage disease are mainly treated with surgery, whereas those with locally advanced disease or lymph node involvement require combined radiotherapy and chemotherapy. However, when a patient is diagnosed with multiple synchronous malignancies of the female reproductive system, standardized treatment guidelines and prognostic data are lacking due to the rarity of this condition. Herein, we present the case of a 66-year-old Asian woman with left ovarian carcinosarcoma, high-grade serous carcinoma of the right ovary and squamous carcinoma of the cervix. Case Presentation A 66-year-old postmenopausal woman with a history of diabetes and hypertension was admitted to our hospital in April 2021 due to abdominal bloating for 10 months and vaginal bleeding for over 2 months. She also reported bilateral lower limb swelling and oliguria. Initial evaluation led to a diagnosis of stage IV ovarian cancer concurrent with stage IB cervical cancer. Her family history was notable for her mother having died of rectal cancer. Gynecological examination revealed a mass in the right adnexa measuring approximately 20 × 18 × 12 cm, clinically suggestive of a large ovarian neoplasm. The cervix appeared slightly atrophied, with mild columnar ectopy. Laboratory tests showed marked elevation of all tumor markers except alpha-fetoprotein (AFP). Liquid-based thin-layer cell smears (TCT) revealed a high-grade squamous intraepithelial lesion (HSIL) and cervical biopsy demonstrated cervical intraepithelial neoplasia grade II or III (CIN II–III). Subsequent endocervical curettage confirmed HPV16-related, well-differentiated invasive squamous carcinoma. Abdominal paracentesis was performed, and cytology of the ascitic fluid revealed numerous malignant cells, and immunohistochemistry was consistent with high-grade serous adenocarcinoma. Computed tomography (CT) imaging showed a 12.5 cm mass in the right ovary and a 10 cm mass in the left ovary, both extending to abdominopelvic peritoneum, omentum and mesentery. For further evaluation, positron emission tomography-computed tomography (PET-CT) demonstrated extensive dissemination of malignant lesions. Additionally, the right inguinal lymph nodes were enlarged, measuring approximately 1.2 cm. Given the large tumor burden, the patient received three cycles of paclitaxel and carboplatin as neoadjuvant chemotherapy. At the end of treatment, re-evaluation by PET-CT demonstrated markedly decreased uptake in previously involved lesions. In addition, previously elevated tumor markers, including CA125, CA153, CA199 and HE4, showed significant reduction. Subsequently, staging surgery was performed, including total hysterectomy, bilateral salpingo-oophorectomy, partial omentectomy, and pelvic and para-aortic lymph nodes dissection. Complete cytoreduction (R0) was achieved. During laparotomy, a left ovarian tumor measuring approximately 12.0 × 10.0 × 10.0 cm and a right ovarian tumor measuring approximately 15.0 × 10.0 × 10.0 cm were observed, both densely adherent to the posterior peritoneum, lateral rectal fossa, and posterior uterine wall. Postoperative histopathological evaluation confirmed the presence of distinct malignancies: cervical squamous cell carcinoma, left ovarian carcinosarcoma, and right high-grade serous carcinoma, with metastases in the right inguinal lymph node. Immunohistochemical staining results were as follows: Cervical lesion: Histological morphology shows moderately differentiated squamous cell carcinoma. Given its typical morphological characteristics, no additional immunohistochemical testing was considered. The diagnosis was established based on clear squamous differentiation characteristics such as cellular keratinization and intercellular bridges observed under H&E staining. Right adnexal lesion (ovary and fallopian tube): The postoperative specimen showed complete hemorrhagic necrosis and cystic degeneration following neoadjuvant chemotherapy. However, in the residual tumor cells, immunohistochemistry revealed CK7 (+), CK (+), ER (+), P16 (+), P53 (mutant overexpression), and WT1 (+), which support a diagnosis of high-grade serous carcinoma (HGSC). Left adnexal lesion: Histologically, it exhibits a clear carcinosarcoma pattern, with a mixture of high-grade serous adenocarcinoma and malignant chondrosarcoma components. Immunohistochemical analysis shows that the adenocarcinoma component is positive for CK7, CK, ER, P16, mutant P53 (overexpressed), and WT1, supporting a diagnosis of high-grade serous carcinoma. The chondrosarcoma component demonstrates positivity for S-100, SATB2, VIM, and mutant P53 (overexpressed), consistent with chondrosarcoma differentiation. The distinct immunophenotypes of these two components confirm the origin of the sarcomatous element. Regarding the metastasis of lymph nodes in the inguinal region, its histological morphology is exactly the same as that of ovarian adenocarcinoma. Therefore, the source of the metastasis was the primary ovarian adenocarcinoma. Based on postoperative staging and pathological assessment, the patient underwent a total of five cycles of adjuvant chemotherapy, which were administered in two sequential phases: two cycles of paclitaxel plus carboplatin (with bevacizumab added in the second cycle), followed by three cycles of paclitaxel plus cisplatin. Despite negative HRD and BRCA testing results, the patient subsequently received maintenance therapy with niraparib at an initial dose of 200 mg once daily (due to baseline body weight <77 kg and platelet count <150 × 109/L), which was later reduced to 100 mg once daily because of thrombocytopenia. This treatment approach resulted in a progression‑free survival of nearly one year. Later, the ovarian cancer progressed, and in March 2024, the patient was readmitted for a liver abscess. Due to her critical condition, she was discharged voluntarily and passed away in April 2024. The timeline of the patient’s entire treatment course is depicted in Figure 1. Timeline of the patient. Discussion The clinical management of multiple primary malignant neoplasms (MPMNs) is challenging, as it requires a balance between treatment priorities among different primary tumors. This case presents a particularly complex scenario of advanced ovarian cancer combined with early-stage cervical cancer, highlighting the principles of multidisciplinary comprehensive therapy for gynecological malignancies. Regarding the origin of the bilateral ovarian tumors in this case, it requires careful interpretation. We strictly followed the Warren and Gates criteria to determine multiple primary malignant tumors; however, due to the large size of both lesions (maximum diameter > 10 cm) and the limited routine pathological sampling, we were unable to confirm the independence and discontinuity of the right high-grade serous carcinoma and the left carcinosarcoma in terms of histology, nor could we rule out the possibility of metastasis between the two. Therefore, we failed to meet the key requirement of excluding mutual metastasis. This uncertainty is also biologically justified: cumulative evidence suggests that both may originate from the epithelium of the fallopian tube and may have a clonal homology possibility; and approximately one-third of ovarian carcinosarcomas are bilateral, and the right lesion cannot rule out the presence of undetected sarcoma components. Thus, based on the current pathological data, it is still difficult to clearly determine whether this case is a triple primary cancer or a bilateral ovarian tumor with metastatic differentiation and possible metastasis, and molecular cloning analysis (such as TP53 mutation spectrum tracking) is needed for determination. Nevertheless, the main clinical value of this report is not the precise classification of tumor origin, but its special presentation - early cervical cancer combined with advanced ovarian cancer (bilateral high-grade tumors). The core treatment challenge lies in balancing the radical treatment of cervical cancer and the best tumor reduction and overall management of advanced ovarian cancer, which is the focus of our subsequent discussion on treatment strategies. It was proved that multiple primary tumors in the female genital tract may correlate with familial syndromes.17 In this case, the patient’s mother died of colorectal cancer, and her previous colonoscopy revealed polyps. Genetic testing was negative for BRCA mutations and positive for MMR protein expression, indicating intact mismatch repair function. These findings suggest a low likelihood of the patient’s having Lynch syndrome or hereditary breast and ovarian cancer syndrome. Other hereditary syndromes were also not considered due to the absence of additional clinical symptoms. This article is the first paper reporting synchronous occurrence of cervical squamous cell carcinoma, ovarian carcinosarcoma in the left ovary, and high-grade serous carcinoma in the right ovary. PET-CT lacks specific imaging criteria for differentiating the primary nature of ovarian masses in preoperative diagnosis. In this case, both CT and PET-CT scans before treatment showed a large cystic-solid mass in both adnexal regions (right 12.5 × 11.5 cm, left 10 × 7.5 cm), accompanied by active metabolism, thickened cervix with focal hypermetabolic foci, extensive thickening of the abdominal and pelvic peritoneum, omentum and mesentery, as well as multiple nodules and a large amount of fluid accumulation; the images only suggested a malignant tumor originating from the adnexa combined with peritoneal implantation and cervical lesions, but could not clearly determine whether the two lesions were independent primary or metastatic relationships. Serum tumor markers showed that CA125 reached 1025.0 U/mL and HE4 >1500 pmol/L, showing extremely elevated levels, which were consistent with the typical characteristics of advanced high-grade serous ovarian cancer. Moreover, the immunohistochemical analysis of ascites showed PAX8 (+), WT1 (+), ER (+), and CK7 (+), while P63 (-) and CDX2 (-), supporting a high-grade serous carcinoma (ovarian origin); the cervical biopsy showed CIN II–III, and the cervical canal scraping showed invasive squamous cell carcinoma. The histological types (adenocarcinoma vs squamous cell carcinoma) and immunophenotypes of the two are completely different, ruling out the possibility of metastasis. In summary, based on the combined evidence of imaging, serology, and pathology, the preoperative tendency is for ovarian high-grade serous carcinoma combined with primary cervical squamous cell carcinoma. The clinical behavior of MPMNs is highly heterogeneous. Table 1 summarizes all cases of synchronous primary malignancies of the cervix and ovary (n = 20) reported in the PubMed database (https://pubmed.ncbi.nlm.nih.gov/). Literature indicates that synchronous tumors have a better prognosis than metastatic ones. Among these cases, 10 patients were diagnosed with ovarian cancer early due to vaginal bleeding, and 8 had favorable outcomes; in contrast, 7 patients were diagnosed at an advanced stage, with delayed diagnosis attributed to endocervical or in situ lesions (one patient had multiple abnormal TCT results but negative biopsies, requiring conization for confirmation) or small ovarian lesions (one case delayed by two years). This suggests that early screening for ovarian cancer is challenging when coexisting with cervical cancer, highlighting the need for enhanced screening strategies. For patients with persistent abnormal TCT results despite negative biopsies, conization should be performed along with close monitoring of the ovaries. Additionally, among the two cases with the same histopathological type as this case, both received gene-guided personalized treatment. One patient with advanced disease also received PD-L1 inhibitor and anti-HER2 targeted therapy,18 while another underwent intraperitoneal chemotherapy during surgery due to peritoneal metastasis, followed by maintenance PARP inhibition postoperatively.19 In our case, due to large tumor size, advanced age, and comorbidities, neoadjuvant chemotherapy was administered prior to surgery, and PARP inhibitors were continued post-surgery despite BRCA negativity. All three patients achieved complete remission, but two progressed and died during follow-up, indicating that personalized treatment may improve short-term outcomes, yet long-term prognosis remains unsatisfactory, underscoring the urgent need for optimization of maintenance strategies. Table 1Reported Cases of Synchronous Ovarian Cancer with Cervical CancerFirst Authors, YearsAgePresentationSiteTumor HistologyTherapyOutcomesFU Months(Refs).Parker et al (1989)45MenorrhagiaOvary, uterus and cervixEndometrioid carcinoma of the ovary (moderately-differentiated), adenocarcinoma of the endometrium (well-differentiated) and adenocarcinoma in situ of the cervixOP + CTNMNM[20]Jobo et al (1991)35Vaginal bleedingOvary, uterus and cervixEndometrioid adenocarcinoma of the ovary, endometrial adenoacanthoma (well-differentiated) and carcinoma in situ of the cervixOP + CTNED25[21]Cumming et al (2000)38MenorrhagiaOvary, uterus and cervixEndometrioid carcinoma of the ovary, endometrioid adenocarcinoma (grade 2) and cervical squamous carcinomaOPNMNM[22]Huang et al (2006)30Abdominal fullness, chest tightness and dyspneaOvary and cervixEndometrioid adenocarcinoma of the ovary (grade 2/3) and endocervical mucinous adenocarcinomaOP + CTDOD8[23]Phupong et al (2007)50MenorrhagiaOvary, uterus and cervixLow malignant potential of the right ovary (endometrioid adenofibroma), mucinous cystadenocarcinoma of the left ovary, endometrial endometrioid adenocarcinoma (well-differentiated) and endocervical adeno-squamous carcinoma (poorly-differentiated)OP + RTDie from pulmonary embolism3[24]Kilciksiz et al (2007)43Vaginal bleedingOvary, uterus and cervixOvarian serous carcinoma (moderately differentiated), endometrial endometrioid adenocarcinoma (moderately-differentiated) and cervical squamous cell carcinoma (moderately-differentiated)OP + CT + RTDOD6[25]Saglam et al (2007)63Postmenopausal bleeding and abdominal distentionOvary, FT, uterus and cervixOvarian mucinous adenocarcinoma, FT papillary adenocarcinoma, endometrial endometrioid adenocarcinoma and endocervical adenocarcinomaOP + CTNED29[26]Atasever et al (2009)50Abdominal fullness and pelvic painOvary, FT, uterus and cervixPapillary serous carcinoma of the left ovary, microinvasive carcinoma in situ of the left and right uterine tubes, endometrial intraepithelial carcinoma of the endometrium and endocervical carcinoma in situ of the uterine cervixOP + CTDie from pulmonary embolism29[27]Hale et al (2011)49Fatigue and abdominal distentionOvary, uterus and cervixOvarian mucinous clear cell and endometrioid carcinoma, endometrial endometrioid adenocarcinoma (well-differentiated) and endocervical endometrioid adenocarcinoma (poorly-differentiate)NACT + OPNMNM[28]Takatori et al (2014)50Vaginal bleedingOvary, uterus and cervixOvarian serous adenocarcinoma, endometrial endometrioid adenocarcinoma and endocervical endometrioid adenocarcinomaOP + CTNED18[29]Chiofalo et al (2016)38Pelvic pain and vaginal bleedingOvary, uterus and cervixOvarian mucinous adenocarcinoma (well-differentiated), endometrial endometrioid adenocarcinoma (well-differentiated) and endocervical mucinous adenocarcinoma (moderately-differentiated)OP + CTNED18[30]Abu-Zaid et al (2017)55Abdominal distention, abdominal pain and vaginal bleedingOvary, uterus and cervixOvarian clear cell carcinoma, endometrial endometrioid adenocarcinoma and cervical squamous cell carcinoma (poorly-differentiated)OPDP3[31]Chai et al (2017)47Postcoital bleedingOvary and cervixEndometrioid adenocarcinoma of the left ovary and cervical adenocarcinomaOP + CT + RTNMNM[32]Wang et al (2019)56Postmenopausal bleedingOvary, uterus, cervix and stomachEndometrioid adenocarcinoma of the right ovary, endometrial endometrioid adenocarcinoma (well-differentiated), endocervical adenocarcinoma and gastric adenocarcinoma (poorly-differentiated)NACT + OPLost to FU after 1 year12[33]Bacalbasa et al (2020)53Postmenopausal bleeding, pelvic pain and weight lossOvary and cervixOvarian serous carcinoma (well-differentiated) and mucinous cervical adenocarcinoma (moderately-differentiated)OP + CTNMNM[34]Hsu et al (2020)42Enlarging pelvic lesion and lower back painOvary, uterus and cervixOvarian mucinous carcinoma (moderately-differentiated), endometrial endometrioid carcinoma and cervical carcinosarcoma (poorly-differentiated)OP + CT + RTNED16[35]Abdelsamia et al (2022)35Lower back pain, dysuria, bilateral hip pain and suprapubic painOvary and cervixBilateral ovarian high-grade serous carcinoma and cervical adeno-squamous carcinomaOP + CT + targeted immunotherapyNMNM[18]Hao et al (2023)51Vaginal bleedingOvary, uterus, cervix and breastPoorly differentiated carcinoma of the right ovary, endometrial endometrioid carcinoma (well-differentiated), cervical neuroendocrine carcinoma (poorly-differentiated) and breast cancerNACT + OP + CTNMNM[1]Xie et al (2024)29Abnormal vaginal dischargeOvary and cervixOvarian immature teratoma (grade 3) and cervical small cell neuroendocrine carcinomaOP + CTNED24[36]Wu et al (2024)47Vaginal bleedingOvary and cervixOvarian high-grade serous papillary carcinoma and cervical non–keratinizing squamous cell carcinomaOP + CT + NiraparibNEDNM[19]Abbreviations: FT, fallopian tube; NACT, neoadjuvant chemotherapy; OP, operation; CT, chemotherapy; RT, radiotherapy; FU, follow up; NM, not mentioned; DOD, died of disease; NED, no evidence of disease; DP, disease progress. Reported Cases of Synchronous Ovarian Cancer with Cervical Cancer Abbreviations: FT, fallopian tube; NACT, neoadjuvant chemotherapy; OP, operation; CT, chemotherapy; RT, radiotherapy; FU, follow up; NM, not mentioned; DOD, died of disease; NED, no evidence of disease; DP, disease progress. Currently, there is no unified clinical guideline for MPMNs.37,38 The management of this patient followed a three-stage treatment strategy. The approach focused on the primary determinant of overall prognosis - advanced ovarian cancer. The surgical management of combination of early-stage cervical cancer and advanced ovarian cancer meets trouble: early cervical cancer demands radical hysterectomy with radiation, whereas advanced ovarian cancer requires maximal cytoreduction prioritizing peritoneal stripping and upper abdominal clearance. In our case, neoadjuvant chemotherapy bridged this gap: three platinum-based cycles shrank both ovarian masses (from 12.5 cm and 10 cm) to resectable dimensions, converting a potentially unresectable pelvis into a field amenable to concurrent radical cervix resection and optimal tumor debulking. Later, an extensive surgical approach was performed, including total hysterectomy, bilateral salpingo-oophorectomy, tumor debulking surgery, and pelvic and para-aortic lymph node dissection. This integrated approach conferred three immediate benefits: (1) negative parametrial and vaginal margins, meeting cervical cancer curative standards; (2) optimal cytoreduction to ≤0.5 cm residual disease; and (3) obviation of the need for pelvic radiotherapy, thereby minimizing long-term radiotherapy-associated toxicities such as myelosuppression and intestinal injury, and establishing a foundation for subsequent full-dose systemic therapy. The third stage focuses on the postoperative adjuvant and maintenance therapy. Both epithelial ovarian cancer and ovarian carcinosarcoma are highly invasive and typically require adjuvant chemotherapy. Accordingly, the patient completed five cycles of paclitaxel combined with platinum-based drugs postoperatively. Adjuvant treatment strategies for multiple gynecological malignancies must be individualized according to tumor type and stage. Maintenance therapy decisions should be guided by postoperative pathology and molecular testing. Multiple clinical studies have confirmed that regardless of the BRCA mutation status or homologous recombination deficiency (HRD) status, niraparib maintenance therapy can bring significant progression-free survival (PFS) benefits to patients with platinum-sensitive recurrent or newly diagnosed advanced ovarian cancer. The NORA39 and NOVA40 studies showed that niraparib could significantly prolong PFS in both gBRCA-mutated and non-mutated populations; the PRIMA study also confirmed that even HRD-negative patients could benefit from first-line niraparib maintenance therapy.41 Therefore, although this case has negative BRCA and HRD status, based on the above evidence of benefits for the entire population and the recommendations of the guidelines,42 choosing niraparib for maintenance therapy has sufficient evidence-based basis, aiming to prolong the platinum-free interval and improve prognosis. This case involves a 66-year-old female patient diagnosed with type 2 diabetes and hypertension. She received neoadjuvant chemotherapy, surgery, and niraparib maintenance therapy. Toxicity management needs to be considered carefully during the whole therapy process: controlling fasting blood glucose <7.0 mmol/L and HbA1c <7.5% during the perioperative period and chemotherapy; switching from oral hypoglycemic drugs to insulin; controlling blood pressure <140/90 mmHg; using G-CSF when there is bone marrow suppression; and administering hospitalization anti-infection treatment for febrile neutropenia; and transfusing platelets <20 × 109/L. During the maintenance treatment stage, since the patient had no BRCA mutations, a baseline weight <77 kg, and platelet count <150 × 109/L, niraparib was administered at an individualized starting dose of 200 mg once daily. Platelet reduction happened within one month of medication, and the dose was reduced to 100 mg once daily to restart the treatment. This indicates that the hematological toxicity is controllable and it is necessary to monitor blood routine examination weekly at the beginning of treatment. Additionally, niraparib is metabolized by carboxylesterase and has no significant influence on the use of antihypertensive and hypoglycemic drugs. For elderly patients with underlying diseases, multidisciplinary collaboration has a major impact on balancing efficacy and safety. The individualized administration experience of niraparib can provide a reference for similar patients. For primary multiple cancers lacking standardized treatment protocols, clinicians need to take into account multiple factors including disease stage, pathological type and patient condition. It is now widely accepted that individualized treatment model centered on multidisciplinary team (MDT) collaboration and incorporating patient preferences represents best practice. Future progress in this field will depend on the updates from ongoing clinical research and the accumulation of additional high-quality evidence. Limitations This study has several limitations. Firstly, the lack of molecular cloning analysis such as next-generation sequencing (NGS) is the main constraint in the diagnosis of this case – although immunohistochemistry (including TP53 overexpression, SATB2, S-100, and CK7) supports the histological classification, it cannot completely rule out the possibility of metastasis and dissemination among the three lesions. Therefore, the classification of triple primary cancer remains a preliminary judgment. Secondly, the exact cause of the patient’s death has not been confirmed by autopsy, and the multiple events such as end-stage liver abscess, bleeding disorders progression, and acute heart failure make it difficult to attribute the death to a single cause. Nevertheless, this case still provides clinical insights for the diagnosis and treatment of synchronous gynecological malignant tumors and emphasizes the necessity of molecular testing and multidisciplinary approaches in the management of rare cases. Conclusion The diagnosis and treatment of multiple primary malignant tumors remain challenging. In terms of diagnosis, conventional pathology is limited by the sampling method and thus is unable to strictly rule out the possibility of mutual metastasis between bilateral ovarian tumors. It is recommended to incorporate systematic multi-site sampling and molecular cloning analysis (such as TP53 mutation spectrum tracking) into the diagnostic process to avoid misjudgment and misleading the staging and treatment. In terms of treatment, when early cervical cancer is combined with advanced ovarian cancer, the goal should be to achieve adequate tumor reduction in the advanced ovarian cancer stage. Sequential surgery should be performed after neoadjuvant chemotherapy; single R0 resection can safely omit pelvic radiotherapy, avoiding myelosuppression and ensuring the implementation of full-dose adjuvant chemotherapy and PARPi maintenance therapy. Even in the absence of BRCA/HRD mutations, niraparib was administered based on evidence from the PRIMA trial. This patient achieved nearly one year of PFS and over three years of OS, highlighting the value of comprehensive genomic analysis. Under multidisciplinary collaboration, precise identification, aggressive tumor reduction, cautious radiotherapy, and evidence-based maintenance therapy may improve the prognosis of such rare and complex cases. Ethics Institutional approval was required for the publication of the case details (approval No. 2024053). Cancer Hospital of Shantou University Medical College has approved the publication of case details. Patient Consent Written informed consent was obtained from the patient prior to her death for publication of this Case report and any accompanying images. Disclosure The author(s) report there is no conflict of interest in this work. References